Combination Therapy for Patients with Primary Sclerosing Cholangitis. Ann Intern Med. 1999;131:943. doi: 10.7326/0003-4819-131-12-199912210-00027
Download citation file:
Published: Ann Intern Med. 1999;131(12):943.
Primary sclerosing cholangitis is a type of liver disease where the ducts that transport bile in the liver become increasingly blocked as time passes. This deadly disease is thought to be an autoimmune disease. Autoimmune means that the disease results when a person develops immune reactions against substances in his or her own body. No treatment is known to be effective at stopping the continuous worsening of this disease. Treatments that keep the immune system in check (immunosuppressants) might help if this is really an autoimmune disease.
The researchers report what happened when they treated patients with primary sclerosing cholangitis with the immunosuppressant drugs azathioprine and prednisolone. They gave these drugs in combination with ursodeoxycholic acid, a drug that helps to dissolve bile caught in the liver ducts. Azathioprine and prednisolone are drugs that suppress the immune system.
The researchers studied 15 patients with primary sclerosing cholangitis at a teaching hospital in Germany.
The researchers gave each of these patients a combination of the drugs azathioprine, prednisolone, and ursodeoxycholic acid and watched them for between 3 and 81 months (41 months on average). The patients had examinations, blood tests, samples of liver tissue taken (biopsies) to be examined under a microscope, and special tests called endoscopic retrograde cholangiography (ERCP). The ERC involves putting a tube down someone's mouth into their intestinal tract and squirting dye into the bile ducts so the degree of blockage will show up on special x-rays.
The blood tests improved in all 15 patients. Ten of the patients had liver biopsies and 6 of these showed improvements. Ten patients had ERCP and only one of the 10 had worsening blockages of the bile duct. Two of the 15 patients had to stop the treatment because of side effects.
Without a comparison group of patients who did not get this combination treatment, we cannot tell for sure that this treatment was responsible for the improvements the researchers saw in these 15 patients.
Combination therapy with drugs that keep the immune system in check may slow the worsening of primary sclerosing cholangitis. A more sophisticated study of this treatment, including a control group, is necessary.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Gastroenterology/Hepatology, Biliary Disorders.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only